Emily Gallagher, MB BCH BAO, MRCPI
NPI: 1700048741
Total Payments
$24,406
2024 Payments
$2,533
Companies
5
Transactions
22
Medicare Patients
418
Medicare Billing
$61,243
Payment Breakdown by Category
Consulting$13,427 (55.0%)
Research$9,692 (39.7%)
Food & Beverage$856.12 (3.5%)
Travel$431.26 (1.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,427 | 7 | 55.0% |
| Unspecified | $9,692 | 5 | 39.7% |
| Food and Beverage | $856.12 | 9 | 3.5% |
| Travel and Lodging | $431.26 | 1 | 1.8% |
Payments by Type
General
$14,714
17 transactions
Research
$9,692
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23,659 | 14 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $284.68 | 3 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $213.15 | 3 | $0 (2023) |
| Amgen Inc. | $124.97 | 1 | $0 (2020) |
| Abbott Laboratories | $123.92 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,533 | 2 | Novartis Pharmaceuticals Corporation ($2,409) |
| 2023 | $6,712 | 3 | Novartis Pharmaceuticals Corporation ($6,663) |
| 2022 | $7,791 | 6 | Novartis Pharmaceuticals Corporation ($7,791) |
| 2021 | $3,753 | 2 | Novartis Pharmaceuticals Corporation ($3,753) |
| 2020 | $124.97 | 1 | Amgen Inc. ($124.97) |
| 2019 | $3,167 | 4 | Novartis Pharmaceuticals Corporation ($3,043) |
| 2017 | $324.68 | 4 | Merck Sharp & Dohme Corporation ($284.68) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/02/2024 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $2,409.44 | Research |
| Study: Research Publication/ Writing Support • Category: Oncology | ||||||
| 01/29/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $123.92 | General |
| Category: Diabetes Care | ||||||
| 12/07/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $48.41 | General |
| Category: DIABETES | ||||||
| 09/09/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $509.29 | Research |
| Study: BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC • Category: Oncology | ||||||
| 01/31/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $6,153.93 | Research |
| Study: Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat • Category: Oncology | ||||||
| 11/21/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $443.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 08/08/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $834.00 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $176.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 06/10/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $1,980.75 | General |
| Category: ONCOLOGY | ||||||
| 03/30/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $3,857.25 | General |
| Category: ONCOLOGY | ||||||
| 12/31/2021 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $2,085.00 | General |
| Category: ONCOLOGY | ||||||
| 04/28/2021 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $1,668.00 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2020 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: Bone Health | ||||||
| 06/08/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $124.74 | General |
| 05/11/2019 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Consulting Fee | Cash or cash equivalent | $2,502.00 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2019 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Travel and Lodging | Cash or cash equivalent | $431.26 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2019 | Novartis Pharmaceuticals Corporation | BYL719 (Drug) | Food and Beverage | In-kind items and services | $109.40 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: DIABETES | ||||||
| 11/15/2017 | Merck Sharp & Dohme Corporation | JANUVIA (Drug) | Food and Beverage | In-kind items and services | $72.40 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/01/2017 | Merck Sharp & Dohme Corporation | JANUVIA (Drug) | Food and Beverage | In-kind items and services | $130.87 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/08/2017 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $81.41 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat | Novartis Pharmaceuticals Corporation | $6,154 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $2,409 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $619.00 | 2 |
| BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC | Novartis Pharmaceuticals Corporation | $509.29 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 91 | 133 | $54,275 | $13,018 |
| 2022 | 3 | 117 | 154 | $64,360 | $16,222 |
| 2021 | 3 | 118 | 174 | $72,085 | $18,854 |
| 2020 | 3 | 92 | 132 | $60,500 | $13,149 |
Total Patients
418
Total Services
593
Medicare Billing
$61,243
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 98 | $42,140 | $10,558 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $11,880 | $2,317 | 19.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 12 | 17 | $255.00 | $142.80 | 56.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 70 | 106 | $45,580 | $11,877 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $18,480 | $4,286 | 23.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 19 | 20 | $300.00 | $59.28 | 19.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 73 | 127 | $54,610 | $14,616 | 26.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 26 | 26 | $17,160 | $4,176 | 24.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 19 | 21 | $315.00 | $63.00 | 20.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 59 | 94 | $40,420 | $8,802 | 21.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 19 | 24 | $13,920 | $3,103 | 22.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 14 | 14 | $6,160 | $1,243 | 20.2% |
About Emily Gallagher, MB BCH BAO, MRCPI
Emily Gallagher, MB BCH BAO, MRCPI is a Endocrinology, Diabetes & Metabolism healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2008. The National Provider Identifier (NPI) number assigned to this provider is 1700048741.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Emily Gallagher, MB BCH BAO, MRCPI has received a total of $24,406 in payments from pharmaceutical and medical device companies, with $2,533 received in 2024. These payments were reported across 22 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($13,427).
As a Medicare-enrolled provider, Gallagher has provided services to 418 Medicare beneficiaries, totaling 593 services with total Medicare billing of $61,243. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location New York, NY
- Active Since 07/01/2008
- Last Updated 02/21/2019
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1700048741
Products in Payments
- PIQRAY (Drug) $20,617
- BYL719 (Drug) $3,043
- JANUVIA (Drug) $203.27
- EVENITY (Biological) $124.97
- FREESTYLE LIBRE 3 (Device) $123.92
- JARDIANCE (Drug) $88.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in New York
Dr. John Bilezikian, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $970,936
Endocrinology, Diabetes & Metabolism $970,936
Anastasios Manessis, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $719,303
Endocrinology, Diabetes & Metabolism $719,303
Stuart Weiss, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $520,227
Endocrinology, Diabetes & Metabolism $520,227
Dr. Brian Levy, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $383,360
Endocrinology, Diabetes & Metabolism $383,360
Recaredo Berbano, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $340,374
Endocrinology, Diabetes & Metabolism $340,374
Dr. Jason Baker, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $308,409
Endocrinology, Diabetes & Metabolism $308,409